B
cell receptor-mediated signaling upon recognition of specific Ag initiates humoral immune response. In addition, costimulatory signaling mediated by CD40 and BAFFR plays important roles in B cell proliferation and Ig production (1) (2) (3) (4) (5) . B cell activation is tightly regulated to limit unwanted responses to self-Ag (6, 7) . Although B cell activation and Ig production are required for an optimal immune response against pathogens, dysregulated B cell activation can lead to increased Ig production and susceptibility to autoimmune disease (8) . Myasthenia gravis (MG) is primarily driven by autoantibodies against self-Ags such as nicotinic acetylcholine receptor (AChR), blocking receptor signaling and resulting in muscle weakness (9) . Although the role of autoantibodies is well defined in MG, the molecular pathways driving B cell activation and autoimmunity are less understood.
The NF-kB pathway is a central signaling pathway in the B cell immune response (10) . NF-kB signaling can be divided into two branches: classical signaling that uses RelA, c-Rel, and p50 dimers, and alternative signaling that uses RelB and p52 dimers. Whereas the classical signaling pathway is required for the survival of most cell types, the alternative pathway is particularly essential for stages of B cell activation such as cell-cycle progression, isotype switching, and plasma cell survival (10) (11) (12) (13) (14) . In addition, the classical and alternative NF-kB signaling pathways are differentially activated: in B cells, the classical signaling pathway is activated by BCR, TLRs, and inflammatory cytokines IL-1, IL-6, and TNF-a, whereas the alternative pathway is activated by CD40, BAFFR, and LTbR (10) . Although the NF-kB members have overlapping homology, the two branches of signaling maintain distinct transcriptional activities and cellular functions (10, 12) . How the two signaling branches of NF-kB maintain distinct functions despite their structural similarities is still relatively unknown.
The Dbc1 gene was initially identified as part of the 8p21 chromosome locus that is deleted in breast cancers (15) . DBC1 has been shown to regulate gene transcription by interacting with nuclear receptors (16) (17) (18) and epigenetic modifiers (19) (20) (21) (22) . Although DBC1 has been studied mostly in the context of cancer and metabolism, little is known about its role in the immune response. Sirt1, a target of DBC1, has been shown to play a regulatory role in the immune response, particularly in the function of macrophages and T cells through the suppression of classical NF-kB member RelA (23) (24) (25) , prompting us to investigate the role of DBC1 in the immune response. Unexpectedly, we found that DBC1 regulates proliferation and Ig production of B cells, by suppressing the transcriptional activity of alternative NF-kB members RelB and p52. Consequently, loss of DBC1 in mice results in increased Ag-specific Ab production when immunized with the protein Ag nitrophenylated-keyhole limpet hemocyanin (NP-KLH) without adjuvant, as well as increased susceptibility to Ig-mediated autoimmune disease experimental autoimmune MG (EAMG). Our findings identify DBC1 as a suppressor of B cell activation, through a novel mechanism by selectively suppressing the alternative NF-kB pathway.
Materials and Methods

Mouse and cell lines
HEK293T and NIH3T3 cells lines were maintained in DMEM (Life Technologies) supplemented with 10% FCS and 1% penicillin/streptomycin. EL4 cell line was maintained in RPMI 1640 supplemented with 10% FCS and 1% penicillin/streptomycin. Dbc1 2/2 mice were used as previously reported (26) . DBC1/Sirt1 double knockout (DKO) mice were generated by crossbreeding with Sirt1 flfl CD19-Cre mice. All mice used in this study were maintained and used at the Northwestern University mouse facility under pathogen-free conditions according to institutional guidelines and animal study proposals approved by the Institutional Animal Care and Use Committee.
Plasmids, Abs, and reagents
PcDNA-Myc-DBC1 plasmid was purchased from Addgene (27) . Abs used for immunoblotting and coimmunoprecipitation were from Bethyl Labo- 
Primary B cell isolation and culture
Primary B cells were negatively isolated from 8-to 12-wk-old mice using Dynabeads Mouse CD43 (Untouched B cells; Life Technologies) per manufacturer's instructions. Purified B cells were maintained at 10 6 /ml in RPMI 1640 (Dibco) supplemented with 10% FBS, 50 mM 2-ME, 100 mM sodium pyruvate, 100 mM HEPES buffer, and 1% penicillin/streptomycin. B cells were activated with goat F(ab) 2 anti-mouse IgM (10 mg/ml; Jackson Immunoresearch), anti-CD40 (1 mg/ml; eBioscience), IL-4 (10 ng/ml), LPS (500 ng/ml), and BAFF (100 ng/ml; Peprotech) as indicated.
For cell proliferation and Ig production assays, purified B cells were stained with Cell Trace (5 mm; Life Technologies) and cultured at 10 6 cells/ml for 5 d with indicated stimuli. After 5 d, cells were subjected to flow cytometry and analysis.
Flow cytometry
Single-cell suspensions were Fc blocked with anti-CD16/32 Ab (eBioscience), stained with the appropriate fluorophore-conjugated Abs, then collected in an Accuri C6 Flow Cytometer or FACS Canto (BD Biosciences). Fluorescence-labeled Abs used include fluorescein isothiocyanate-conjugated anti-mouse IgA, PE-conjugated anti-CD138, allophycocyanin-conjugated anti-IgG1 (BD Biosciences), and Peridininchlorophyll Cy5.5-conjugated anti-B220 (Biolegend). Where appropriate, biotin-labeled anti-IgA and peanut agglutinin (PNA) (Vector Laboratories) were used followed by allophycocyanin-conjugated streptavidin (Biolegend). For intracellular staining of Ig, cells were fixed and permeabilized using the CytoFix/Perm Kit (BD Biosciences) per manufacturer's instructions, then incubated with 1:4003 dilution of isolated serum in 1% BSA, followed by staining with the appropriate fluorophore-conjugated Abs.
Cell-cycle analysis
A total of 2 3 10 6 B cells was incubated with 5-ethynhl-29-deoxyuridine (Life Technologies) at 37˚C, 5% CO 2 for 2 h, then fixed in 4% formaldehyde at room temperature (RT) for 15 min. Cells were then washed with PBS, permeabilized with 0.1% Triton X-100, and stained with Alexa 488-coupled azide for 45 min. Cells were washed, then stained with 7-amino actinomycin D 5 min before flow cytometry analysis.
For propidium iodide staining, cultured primary B cells were fixed overnight at 220˚C in 70% ethanol, then washed with PBS twice before incubation with propidium iodide/RNaseA solution (Biolegend) for 30 min at RT. Cells were analyzed by flow cytometry.
TUNEL staining
Cells were fixed with 4% formaldehyde for 15 min, washed with PBS, then permeabilized with 0.5% Tween 20 for 15 min. Cells were then washed again before labeling with 50 ml TdT and biotin-conjugated dUTP mixture (Millipore) for 45 min at 37˚C. Cells were then washed and stained with FITC-conjugated avidin, and analyzed by flow cytometry for apoptosis. (20-30 times) . Mice were graded according to the following scale as previously described: 0 = normal posture and mobility at baseline and after exercise; 1 = normal at rest but with muscle weakness shown by hunchback posture, restricted mobility, and difficulty in raising the head after exercise; 2 = muscle weakness without exercise during observation period; 3 = dehydrated and moribund with muscle weakness; and 4 = dead (28) . Sera were collected on days 14, 28, and 42 for ELISA, and splenocytes were isolated on day 42 for flow cytometry analysis.
Immunizations
ELISA
Ninety-six-well flat-bottom plates were coated overnight at 4˚C with 1 mg NP-BSA, 0.1 mg tAChR, or 0.1 mg Mus musculus-derived (mAChR) per well to detect Abs against NP-KLH, tAChR, and mAChR, respectively. For detection of total Ig levels, 50 ng purified anti-mouse Abs for the specific isotypes was used. Wells were then blocked with 1% BSA at RT for 2 h, then incubated with mouse sera at 1:200-10,000 dilutions overnight at 4˚C. Biotin-coated secondary Abs against specific Ig were added and incubated for 1 h at RT, followed by avidin-HRP and TMB substrate (Thermo Scientific). Absorbance at 450 nm was detected using FilterMax F5 microplate reader (Molecular Devices).
Bone marrow chimera
Bone marrow was isolated from 2 pairs of Dbc1 2/2 (45.2) and congenic B6.SJL (45.1) mice, mixed at a 1:1 ratio, and 5 3 10 6 cells were administered i.v. into each lethally irradiated B6.SJL recipient mouse. After 6 wk, mice were sacrificed and reconstituted splenocytes were analyzed by flow cytometry. Recipient mice were fed with water supplemented with sulfamethoxazole and trimethoprim during the entire duration.
RNA isolation and microarray analysis
A total of 5-10 3 10 6 primary B cells pooled from 3 pairs of mice were cultured with indicated stimuli for 4 h at 37˚C, 5% CO 2 . RNA was then isolated using the Qiagen RNeasy kit per manufacturer's instructions. A total of 1 mg isolated RNA was subjected to microarray analysis using the MouseRef8-v2.0 BeadChip Kit (Illumina) at the University of Chicago Genomics Core Facility. Heat map was generated using Cluster (Eisen) and TreeView software. Functional annotation analysis was performed using Database for Annotation, Visualization and Integrated Discovery (DAVID) v6.7. Response elements on genes were identified from Genecards.org. Microarray data have been submitted to Gene Expression Omnibus database and can be accessed at http://www.ncbi.nlm.nih.gov/geo (accession number GSE61029).
Real-time PCR
A total of 10 6 cells was lysed in TRIzol (Invitrogen), and RNA was isolated per manufacturer's instructions. One microgram isolated RNA was then reversed transcribed using qScript cDNA synthesis kit (Quanta BioSciences). Real-time PCR was performed in duplicate wells using the iCycler Sequence and SsoFast SYBR Green Supermix (BioRad). Relative expression was normalized to expression of Actb. Primers used in this study are shown in Supplemental Table 1 .
DNA binding assay
Nuclear extracts from cultured primary B cells were isolated using the Nuclear Extract Kit (Active Motif) per manufacturer's instructions, and nutated with biotin-conjugated 21-mer DNA probe (5 ng; Life Technologies), streptavidin-conjugated agarose (Sigma-Aldrich) in PBS containing protease inhibitor mixture. Agarose-DNA-protein complex was then washed, boiled in 43 Laemmli buffer, then subjected to SDS-PAGE and Western blot.
ChIP
Primary B cells were stimulated with anti-CD40 and IL-4 for 4 or 16 h, cross-linked with 10% formalin, and subjected to ChIP using the ChIP Assay Kit (Millipore) per manufacturer's instructions. In brief, 2 3 10 6 cells were lysed with SDS lysis buffer. Cell lysates were sonicated, and 3% of cell lysate was removed and used to determine the total amount of target DNA in input. Remaining cell lysates were diluted in ChIP dilution buffer. Immunoprecipitation was performed with each of the indicated Abs (3 mg) at 4˚C overnight. Immune complexes were then mixed with salmon sperm DNA/protein agarose 50% slurry at 4˚C for 1 h. After immunoprecipitates were washed sequentially with low-salt buffer, high-salt buffer, LiCl wash buffer, and Tris EDTA, DNA-protein complexes were eluted with elution buffer, and cross-linking was reversed. Genomic DNA was extracted using phenol/chloroform, and ethanol-precipitated DNA was resuspended in Tris EDTA. Primer sequences are available upon request.
Statistical analysis
Student t test was used to calculate statistical significance for ELISA, cellcycle analysis, proliferation assay, flow cytometry analysis, and Western blot densitometry analysis. Fisher's exact test was used to calculate enrichment of genes in our functional annotation analysis. A p value #0.05 was considered significant. (29), whereas proliferation was indistinguishable from WT upon anti-BCR and LPS stimulation (Fig. 1A, 1B) . We further examined whether the increased percentage of dividing cells in Dbc1 2/2 B cells was due to accelerated cell-cycle progression or protection from apoptosis. The increased proliferation in Dbc1 2/2 B cells correlated with accelerated cell-cycle progression, because the number of G 2 /M-phase cells were increased when cultured with anti-CD40 (Fig. 1C, 1D ). In contrast, deletion of DBC1 does not affect apoptosis, because the number of apoptotic cells in Dbc1 2/2 B cells measured by TUNEL staining were comparable with WT (Supplemental Fig.  2A, 2B ). Therefore, DBC1 negatively regulates B cell proliferation, likely by suppressing cell-cycle progression initiated by CD40 stimulation.
Results
Dbc1
In addition to B cell proliferation, CD40 and BAFFR signaling are known to promote isotype switching in B cells (30, 31 suggesting that the number of IgG1 + cells is increased, but IgG1 production per-cell basis is unchanged (Supplemental Fig. 2C,  2D ). In addition, Dbc1 2/2 B cells showed significantly increased IgA production when stimulated with LPS plus the alternative NF-kB agonist BAFF, but not with LPS alone (Fig. 1E ). Similar to IgG1, the number of IgA-producing cells is increased, whereas IgA per-cell basis is comparable between WT and Dbc1 and Dbc1 2/2 B cells (Supplemental Fig. 2E, 2F ), suggesting that DBC1 specifically regulates alternative NF-kB signaling. These results suggest that DBC1 suppresses B cell activation downstream of specific receptors such as CD40 and BAFFR.
DBC1 regulates B cell activation in a cell-intrinsic manner
Because DBC1 is systemically deleted in our mouse model, we performed a bone chimera experiment to study whether DBC1 inhibits B cell activation in a cell-intrinsic manner. Bone marrow cells derived from Dbc1 2/2 mice were mixed at a 1:1 ratio with those from congenic B6.SJL mice, transferred into lethally irradiated B6.SJL recipients, and analyzed 6 wk after transfer. Dbc1 2/2 (CD45.2) lymphocytes were significantly increased in proportion compared with WT (CD45.1) lymphocytes, which is predominantly due to an increase in KO B220 + cells ( Fig. 2A, 2D ). To confirm this, we detected a significantly increased percentage of B220 + IgM + B cells in the CD45.2 + lymphocyte population compared with the CD45.1 + cells (Fig. 2B, 2E ), suggesting that DBC1 has an intrinsic suppressive function on B cell proliferation. Moreover, consistent with our in vitro B cell activation results (Fig. 1) , Dbc1 2/2 B cells from the recipient mice showed increased proliferation and IgG1 and IgA expression upon in vitro stimulation with anti-CD40 and BAFF, respectively, when compared with that of WT B cells (Fig. 2C, 2F -H). These results reveal that DBC1 has an intrinsic suppressive function in B cell proliferation and IgG1 and IgA production.
DBC1 suppression of B cell activation is independent of Sirt1
One of the best characterized functions of DBC1 is its suppression of Sirt1, a histone deacetylase that inhibits classical NF-kB activity by interacting with RelA (34) (35) (36) . ) and crossing to mice with CD19 promoter-driven Cre recombinase (CD19-Cre). However, when stimulated with anti-CD40, DKO B cells showed a similar increase in proliferation, cell-cycle progression, and IgG1 production to that observed in Dbc1 2/2 B cells (Supplemental Fig. 3 ).
As a control, Sirt1-null B cells responded to CD40 stimulation at similar levels to WT B cells. Thus, Sirt1 appears to be dispensable for B cell response upon CD40 stimulation, and DBC1 suppression of B cell proliferation and Ig production is independent of Sirt1. Taking the bone marrow chimera and DKO experiments together, we conclude that DBC1 regulates B cell proliferation through a B cell-intrinsic, Sirt1-independent mechanism.
Microarray analysis reveals that proliferative genes and NF-kB target genes are upregulated in Dbc1 (Fig. 3A) . In contrast, many genes involved in inflammation were downregulated (Fig. 3A) . In support of our discovery that Dbc1 gene deletion leads to increased B cell growth upon CD40 stimulation, the significant enrichment of proliferative genes was observed under CD40, but not under BCR-stimulated conditions (Fig. 3B, 3C) . We attempted to identify specific signaling pathways affected by the deletion of Dbc1 gene by analyzing response elements present in genes differentially expressed by .4-fold in Dbc1 2/2 B cells.
Among the genes that were upregulated and downregulated, respectively, NF-kB response elements were present in the largest percentage of genes, both in upregulated and downregulated gene groups (Fig. 3D) , indicating that NF-kB signaling is indeed dysregulated in Dbc1 2/2 B cells. Thus, these microarray results affirm our observation that DBC1 suppresses the expression of cell-cycle-related genes in B cells, in particular, those stimulated by CD40 and NF-kB signaling.
DBC1 selectively suppresses alternative NF-kB pathway in B cells
Our findings so far implicate that the alternative NF-kB pathway is regulated by DBC1 in B cells. Interestingly, based on our microarray data, NF-kB targets were both upregulated and downregulated in Dbc1 2/2 B cells, leading us to speculate that DBC1 might differentially regulate different branches of NF-kB signaling. To test whether DBC1 selectively inhibits specific NFkB members, we incubated the cell lysates of WT and Dbc1
2/2
B cells with a biotinylated DNA probe containing a kB-consensus sequence, and avidin-conjugated agarose. DNA-bound NF-kB members in WT and Dbc1 2/2 B cell lysates were then pelleted and detected by Western blot. Indeed, we found that the DNAbinding activity of alternative NF-kB members RelB and p52 was significantly increased in activated Dbc1 2/2 B cells, whereas the
DNA-binding levels of classical NF-kB transcription factors
RelA, c-Rel, and p50 were comparable with WT (Fig. 4A, 4B ), supporting our initial speculation that DBC1 selectively suppresses alternative NF-kB signaling. In contrast, protein levels of each NF-kB member in the nuclear extracts of WT and Dbc1
2/2
B cells were comparable (Fig. 4A, input panels) , indicating that loss of DBC1 results in increased RelB:p52 DNA binding activity, but not its nuclear translocation.
DBC1 suppresses RelB binding at target gene promoters
To confirm that DBC1 suppresses transcriptional activity of RelB at the promoters of NF-kB target genes, we compared RelB promoter-binding activity between WT and Dbc1 2/2 B cells by ChIP. We chose Birc5, cyclinB1 (CCNB1), and CDC20, which are proliferation-inducing genes differentially upregulated in Dbc1 2/2 B cells (Fig. 3E) , and have predicted NF-kB response elements, as our ChIP gene targets. We observed minimal promoter binding of RelB in WT B cells during the early stage of CD40 stimulation (Fig. 5A ). In contrast, Dbc1 2/2 B cells had increased RelB binding at the promoters of all three selected genes at early time points of CD40 activation, even in unstimulated B cells (Fig. 5C) , indicating that the loss of DBC1 leads to increased RelB promoter binding activity in B cells. RelB binding at the promoter region of Ciap2, a known target of both classic and alternative NF-kB (37), was also increased, confirming that RelB DNA-binding activity is increased at target gene promoters (Fig. 5A) To investigate the role of DBC1 in vivo, we tested the Ag-specific immune response of WT and Dbc1 2/2 mice. Upon immunization with NP-KLH emulsified with the CFA and boosted with NP-KLH/IFA on day 7, the levels of NP-specific Abs in the sera of Dbc1 2/2 mice were similar to those of WT mice (Fig. 6A) .
However, when mice were immunized with NP-KLH without adjuvant, Dbc1 2/2 mice showed an increased Ag-specific response, because the levels of NP-specific Ig including the IgG1, IgG2a, IgG3, and IgA, but not IgM, isotypes were significantly increased in Dbc1 2/2 mice (Fig. 6B) . As expected, when immunized with NP-KLH without adjuvant, WT mice showed minimal increase in total serum Ig. The increased serum IgG and IgA levels in Dbc1 2/2 mice are supported by detection of increased NPspecific IgG1-and IgA-expressing B cells in the spleen by flow cytometry (Fig. 6C, 6D (Fig. 7A) . As a control, WT littermates immunized under the same conditions did not develop disease symptoms. In agreement with the clinical score, increased plasma cell population was detected in Dbc1 2/2 mice 42 d after immunization (Fig. 7B-D) . Similar to NP-KLH immunization, Ag-specific IgG1 and IgA against tAChR was increased in Dbc1 2/2 mice sera (Fig. 7E ). Most interestingly, Dbc1 2/2 mice sera had significantly greater levels of cross-reactive IgG1 and IgG2a against mAChR (Fig. 7F ), indicating that Dbc1 2/2 mice are indeed more prone to autoimmunity through production of cross-reactive autoantibodies. Based on our discovery, we propose a working model of DBC1 suppression of unwarranted B cell activation (Fig. 7G, 7H ). DBC1 suppresses alternative NF-kB transcriptional activity, which, in turn, negatively regulates B cell activation, proliferation, and Ig production. When DBC1 is absent in B cells, suppression of RelB: p52 is lost, allowing for gene transcription, even in suboptimal stimulation conditions, such as presence of Ag without adjuvant. The loss of DBC1 suppression of RelB:p52 results in B cell proliferation and Ig production, leading to increased Ig levels in mouse sera upon immunization and higher susceptibility to autoimmune diseases such as EAMG. Therefore, through this study, we identify DBC1 as a novel suppressor of B cell activation by inhibiting alternative NF-kB signaling pathway.
Discussion
In this study, we identify a novel function of DBC1 as a negative regulator of B cell activation by suppressing alternative NF-kB transcriptional activity upon CD40 and BAFF stimulation. This conclusion is supported by the following discoveries: first, loss of DBC1 results in increased B cell proliferation as well as IgG1 and IgA production, specifically in response to CD40 and BAFFR stimulation. Second, bone marrow chimera and Dbc1 2/2 Sirt1 fl/fl CD19-Cre DKO studies indicate that DBC1 suppresses B cell proliferation and Ig production in a B cell-intrinsic, Sirt1-independent manner. Third, microarray analysis reveals that DBC1 suppresses the expression of genes in cell-cycle progression, most of which are NF-kB targets. Fourth, DBC1 deficiency leads to the elevated RelB:p52 binding activity on the promoters of target genes during the early stage of B cell activation upon CD40 and BAFFR stimulation. Finally, loss of DBC1 results in significantly increased levels of Ag-specific IgG and IgA in mice when immunized with Ag in the absence of adjuvant, as well as increased susceptibility to EAMG. Accumulated evidence suggests that CD40 and BAFFR signaling are critical in regulating B cell activation (7, 40) . Activation of CD40 and BAFF leads to the activation of alternative NF-kB signaling, which, in turn, promotes cell-cycle progression, germinal center formation, isotype switching, and plasma cell survival (12, 41, 42) . We propose that the loss of DBC1 regulation of RelB activity results in increased CD40 signaling. In support of our hypothesis, promoter-binding activity of RelB is enhanced in The increased Ig production in Dbc1 2/2 mice when immunized without adjuvant is particularly interesting, in light of the fact that protein immunization without adjuvant produces a minimal immune response and can produce a tolerizing effect (43, 44) . One of the reasons for the tolerizing effect of immunization without adjuvant is the absence of CD40 signaling (45) . Conversely, increased CD40 signaling has been shown to overcome the tolerizing effects of immunization without adjuvant, at least in CD8 + cytotoxic T lymphocytes (44 Our microarray results show that loss of DBC1 results in the upregulation of a subset of NF-kB target genes and downregulation of another subset of target genes. One possibility is that DBC1 differentially regulates the two branches of NF-kB signaling, that is, indirectly promoting classical signaling through Sirt1 inhibition, whereas suppressing alternative signaling pathway through mice have reduced inflammatory cytokine production in the liver when fed a high-fat diet largely in an Sirt1-dependent manner (26) . However, previous laboratory data using Sirt1-null mice, as well as our experiments using Dbc1 2/2 Sirt1 fl/fl CD19-Cre mice, indicate that Sirt1 has minimal effect on B cell function. In addition, using ChIP assays, we did not detect decreased RelA DNAbinding activity in Dbc1 2/2 B cells, which one would expect with increased Sirt1 activity. Another possible reason for the decrease in inflammatory cytokine production is that alternative NF-kB signaling has anti-inflammatory functions in B cells. Indeed, alternative NF-kB signaling has been shown to control inflammation, at least in macrophages (46) (47) (48) . Thus, our findings suggest that the suppressive function of DBC1 on B cells is an outcome of its selective inhibition of RelB activity, as opposed to an indirect outcome of increased Sirt1 activity. In addition, that DBC1 suppresses the alternative NF-kB transcription factors RelB/p52 is unlikely because of the altered expression and/or transcriptional activities of other NF-kB transcription factors, because neither the protein expression levels of RelA, cRel, and p50 nor their promoter binding activity in DBC1-null B cells is changed compared with that of WT controls (Fig. 4) . The noncanonical NF-kB pathway is implicated in the regulation of B cell development, particularly marginal zone and transitional B cell populations (49) (50) (51) . However, we did not detect increased populations in our mouse model (Supplemental Fig. 1 ). One possibility is that loss of DBC1 simultaneously regulates other cell types, which might mask the effects of increased RelB activation in B cell development. Indeed, although we did not see an increase in B cell populations in mice with germline deletion of DBC1, bone marrow chimera experiments show that Dbc1 2/2 B cell population is increased in the recipients 6 wk after the adoptive transfer ( Fig. 2A, 2B, 2D, 2E ), suggesting that although DBC1 regulates B cell proliferation in a cell-intrinsic manner, loss of DBC1 in other cells types in the germline deletion mice might antagonize the B cell hyperproliferative phenotype.
We observed that the Ag-specific IgG1 and IgA are increased in Dbc1 2/2 mice, suggesting that DBC1 regulates isotype switching in B cells. Although isotype switching in B cells is partly dependent on external cues such as T cell and dendritic cell priming (52) (53) (54) , neither the activation nor differentiation of T cells was altered by Dbc1 gene deletion in T cells (data not shown). Together with our data that isolated Dbcl 2/2 B cells produce more IgG1 and IgA, but not IgM, upon in vitro CD40 stimulation, our discoveries imply that DBC1 is involved in isotype switching at least in a cell-intrinsic manner. CD40L and BAFF have been widely reported to induce isotype switching, particularly these two isotypes (31, 55) . The alternative NF-kB signaling pathway has also been shown to be important in IgG and IgA class switching (50, 56) . In addition, it is also possible that the increased production of class-switched isotypes is a result of accelerated cellcycle progression in Dbc1 2/2 B cells, because it has been shown that class switching is linked to cell division, with IgG1 and IgA expressed at higher frequency, whereas IgE requires more cell divisions (30) . Thus, the increased IgG and IgA production in Dbc1 2/2 mice is probably a result of both accelerated cell-cycle progression and increased sensitivity to BAFF or CD40L-induced isotype switching. In summary, our study reveals that DBC1 suppresses B cell proliferation and Ig production. DBC1 suppresses B cell activation by regulating alternative NF-kB transcriptional activity at target gene promoters. As a result, Dbc1 2/2 B cells are hyperactivated, leading to increased Ig levels in Dbc1 2/2 mice upon immunization under suboptimal conditions, and increased susceptibility to EAMG. Taken together, our data reveal a novel regulatory mechanism by DBC1 on the alternative NF-kB pathway, as well as a novel checkpoint function of DBC1 in B cell activation.
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